

1
2
3
4
5
6
7
8
9
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

13
14
15
16
TITLE: Composition and method for treating
Vulvodynia

17
18
19
20
21
22
23
INVENTORS: W. Jerry Easterling
William P. Fitch

1

2 BACKGROUND OF THE INVENTION

3

4 1. Field of The Invention

5

6 The present invention relates to medical treatments
7 pertaining to vulvodynia.

8

9 2. Background Information

10

11 Vulvodynia is characterized by unexplained vulvar pain
12 that can cause physical disability, sexual dysfunction,
13 limitation of normal daily activities, and psychological
14 difficulties.

15 The problem often becomes chronic, lasting for years.
16 There are four basic types of vulvodynia: (1) vulvar
17 vestibulitis (2) dysesthetic vulvodynia (3) vulvar dermatoses
18 and (4) cyclic vulvovaginitis. Many patients are misdiagnosed
19 or not diagnoses at all. Pain is not always accompanied by
20 visible tissue changes, thereby complicating an accurate
21 diagnosis. Vulvar vestibulitis and dysesthetic vulvodynia are
22 the most common.

23 The etiology of the disease is unknown. However, it has
24 been hypothesized that viral, fungal and bacterial assaults,
25 allergic reactions, and an autoimmune response to the body's
26 own chemistry may play a role in the disease process.

1 Irritation of the muscles that support the uterus, bladder and
2 rectum as well as irritation of the nerves of the vulva tissue
3 may result in the painful symptoms associated with Vulvodynia.

4 Empirical evidence indicates that approximately fifteen
5 percent of the adult female population may suffer from
6 Vulvodynia at sometime during their lifetime. Approximately
7 seventy percent of women with Vulvodynia are white, have fair
8 complexion, and are of child bearing age. A study published
9 in the Journal of Urology in May of 1997 suggested that ten
10 percent of women with interstitial cystitis also have symptoms
11 of Vulvodynia.

12 Many patients experience difficulty in walking,
13 sensitivity to clothing touching the vaginal area, difficulty
14 with sexual activities due to pain, difficulty in sitting for
15 long periods, and mild to intense pain described as burning,
16 stinging, or itching.

17 Treatments for vulvodynia include oral medications such
18 as antihistamines, tricyclic antidepressants; topical
19 estrogens; and anticonvulsants; physical therapy and
20 biofeedback; Interferon intralesional injections; low
21 oxalate diet; oral calcium citrate; laser therapy; and
22 surgery. Laser and surgical treatment complications include
23 hematoma, wound dehiscence, uneven healing, and stenosis of

the Bartholin's duct with cyst formation. There is no known
cure for Vulvodynia.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a novel medicament to be used for the treatment of Vulvodynia.

It is another object of the present invention to provide a novel medicament and unobvious medicament for the treatment of Vulvodynia, which medicament is more effective than existing means for treatment.

In satisfaction of these and related objectives, Applicant's present invention provides the vaginal application of a calcium channel blocker agent (preferably in suppository form) and associated methodology for use thereof, through the use of which Vulvodynia may be effectively, noninvasively, cost effectively, and painlessly treated.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

The preferred embodiment of the medicament of the present invention is a vaginal suppository which has demonstrated relief from the symptoms of Vulvodynia in as little as ten days of treatment.

1 In the preferred embodiment, the primary active
2 ingredient of the vaginal suppository is Diltiazem
3 Hydrochloride, USP, a benzothiazepine calcium channel blocker.
4 However, it should be understood that other calcium channel
5 blockers (topically applied, may provide similar relief.
6 Others include Verapamil, a diphenylalkylamine,
7 dihydropyridines, and the fast sodium inward channel
8 inhibitor, Bepridil.

9 The preferred Diltiazem-based vaginal suppository
10 formulation follows:

Diltiazem 50mg Vaginal Suppository	30 each
Diltiazem Hydrochloride, USP	1.50 Gm
Silica Gel, micronized	0.45 Gm
Base MBK (Fatty Acid)	32.85 Gm

11 Melt the Base MBK at 50 degrees Centigrade. Triturate the
12 Diltiazem with the Silica Gel. Using a wire mesh strainer,
13 sprinkle the powdered mixture into the melted base with
14 stirring. Remove from heat and continue stirring until a
15 uniform suspension exists. Pour into suppository shells and
16 allow to cool at room temperature. Heat seal the open ends of
17 the suppository shells. STORE IN REFRIGERATOR at 4 degrees
18 Centigrade.

1 The recommended single dose of the Diltiazem Vaginal
2 Suppository contains 50mg of Diltiazem and is contained in
3 1.16 Gm of the preferred embodiment of the suppository.

4 Packaging in which the suppositories are dispensed to
5 patients should be labeled with the following legend: STORE
6 IN REFRIGERATOR.

7 The patient is to insert vaginally one suppository once
8 or twice daily, depending on patient response as measured by
9 the patient's physician. During treatment, the patient's
10 progress should be evaluated by the physician at least every
11 thirty days.

12 It should be noted that Diltiazem is commonly given
13 orally to treat hypertension or cardiac arrhythmias. Patients
14 should be counseled to report any side effect that could
15 relate to blood pressure changes or noticeable heart rate
16 changes. Any vaginal mucosa irritation should also be
17 immediately reported.

18 It is unclear how the medicament of the present invention
19 works to relieve the symptoms of Vulvodynia. The inventor
20 believes that upon successful absorption of the Diltiazem into
21 the vaginal mucosa, that the calcium channel blocking
22 properties of the Diltiazem may exert an antivasoconstrictor
23 activity or initiate a non-vascular process such as serotonin

1 release or serotonin and histamine receptor blockade. The
2 inventor also believes that after repeated use of the
3 medicament, that a tissue remodeling of damaged or scarred
4 tissue may occur, resulting in a healthier tissue accompanied
5 by resolution of symptoms. The tissue remodeling process
6 consists of the calcium channel blocker medication initiating
7 the production of collagenase within the diseased tissue which
8 initiates the remodeling process while the drug also causes a
9 reduction in the production of fibroblasts associated with the
10 production of scar tissue.

11 The medicament of the present invention has also shown
12 efficacy in the treatment of symptoms associated with
13 Interstitial Cystitis when used vaginally once or twice a day.
14 This indicates that the present medicament has application
15 well beyond the treatment of Vulvodynia, and promises relief
16 of symptoms in any disease of similar mechanisms or physical
17 manifestations like those of Vulvodynia.

18 Various modifications of the disclosed embodiments, as
19 well as alternative embodiments of the inventions will become
20 apparent to persons skilled in the art upon the reference to
21 the description of the invention. It is, therefore,
22 contemplated that the appended claims will cover such
23 modifications that fall within the scope of the invention.